Melanin shows potential as new drug target for obesity

Oct 29 2008

As millions of Americans gear up for the Thanksgiving holiday, a new research report published online in The FASEB Journal, may provide some relief for those leery of having a second helping.

In the report, researchers describe a discovery that may allow some obese people avoid common obesity-related metabolic problems without actually losing weight: they make a common antioxidant, melanin, in excess. Even more promising is that some of the antioxidant drugs that can mimic the melanin effect are FDA-approved and available. This availability would greatly speed the development of new treatments, should they prove effective in clinical trials.

The researchers made the unexpected discovery--fat cells in obese people produce melanin in excess--when they were comparing fat cells of obese people to those of people with normal weight. After the comparison, they found that the gene responsible for making melanin was working in "overdrive" in the fat cells of obese people. The finding was then confirmed using additional laboratory tests. Melanin is a common antioxidant responsible for skin and eye color.

Ancha Baranova, one of the study's researchers from George Mason University and INOVA Fairfax Hospital says, "Most scientific efforts aim at making obese individuals lose weight, but this has proven difficult. Hopefully, this study will lead to a drug that keeps obese individuals healthy, reducing the cost-burden to society as well as some of the stigma associated with this condition."

According to the U.S. Centers for Disease Control and Prevention, the prevalence of obesity in 2005� was about 1 in 3 for men and women. Obesity increases the risk of diseases and health conditions, such as high blood pressure, osteoarthritis, dyslipidemia, Type 2 diabetes, coronary heart disease, stroke, gallbladder disease, sleep apnea and respiratory problems, and some cancers.

"No pill can replace a healthy diet and exercise, yet," said Gerald Weissmann, MD, Editor-in-Chief of The FASEB Journal, "but this could be a major advance for physicians looking for a safe drug target in their search to keep obese patients healthy while their weight becomes normal."